Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive disease that originates from lymphocytes and develops in the central nervous system. There is no standard consolidation/maintenance therapy for PCNSL. While there exists a variety of options, the high chance of inferior outcome...
Main Authors: | Bota, D. (Author), Du, S. (Author), Kong, X.-T (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
by: Danuta Krasowska, et al.
Published: (2020-09-01) -
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
by: Anna Mair, et al.
Published: (2021-09-01) -
Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice
by: VI Vorob’ev, et al.
Published: (2019-03-01) -
Approaches to the prevention and therapy of ibrutinib-associated bleeding in adult patients
by: E. V. Volchkov, et al.
Published: (2018-10-01) -
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
by: Denlinger NM, et al.
Published: (2018-03-01)